CYduct Diagnostics is focused on transformative products that will enable physicians to intervene at the earliest stages of breast cancer.
The company currently develops, produces, and markets medical devices for the risk assessment, identification, diagnosis and ultimately treatment of early-stage breast cancer. All from within the mammary ductal system, where 95% of all breast cancer originates. Its core clinical activities are focused on the proteomic analysis of protein biomarkers associated with breast cancer which are found within ductal fluid.